Why IQVIA’s recent moves are drawing fresh attention

IQVIA Holdings (IQV) has been back in focus after launching its IQVIA.ai platform with NVIDIA, buying drug discovery assets from Charles River Laboratories, and teaming up with the Duke Clinical Research Institute.

These moves, along with ongoing share buybacks and IQVIA’s top ranking on Fortune’s World’s Most Admired Companies list, are prompting investors to reassess how the stock’s current return profile lines up with its life sciences role.

Even with new AI and research partnerships in play, the share price has pulled back, with a 90 day share price return of a 30.73% decline and a year to date share price return of a 25.75% decline. However, the 1 year total shareholder return of 10.88% shows a different picture for longer term holders.

If IQVIA’s AI push has caught your attention, it can also be worth scanning for other healthcare names using artificial intelligence through our 31 healthcare AI stocks

With IQVIA trading at $167.34, showing a 90-day share price decline of 30.73% and an estimated intrinsic discount of 46.57% on some valuations, investors may question whether there is meaningful upside potential or whether the market is already fully reflecting expectations for future growth.

Most Popular Narrative: 33.1% Undervalued

Against the last close of $167.34, the most followed narrative places IQVIA’s fair value at $250, implying a sizeable valuation gap that hinges on future earnings power and cash generation assumptions.

Accelerated adoption of AI-driven analytics and data solutions, supported by strong client demand and high-profile industry partnerships like NVIDIA, positions IQVIA for improved operational efficiency, faster project execution, and differentiation, which should support future revenue growth and eventual margin expansion as AI capabilities scale.

Curious what has to happen for that valuation to make sense? The narrative leans on steady revenue gains, higher margins, and a richer earnings multiple. The exact mix of those moving parts is where the story really gets interesting.

Result: Fair Value of $250 (UNDERVALUED)

However, that upside story could crack if CRO pricing pressure bites harder, or if regulatory and drug pricing uncertainty keeps delaying client decisions and new project awards.

Next Steps

Seeing both risks and rewards in the story so far, it makes sense to review the numbers yourself and decide quickly where you stand with IQVIA by looking over its 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If IQVIA has you thinking more broadly about your portfolio, do not stop here. Use the Simply Wall St screener to surface fresh ideas that fit your goals.

• Target potential upside with a curated set of undervalued names by checking the 57 high quality undervalued stocks.
• Prioritise resilience by focusing on companies with stronger finances through the solid balance sheet and fundamentals stocks screener (41 results).
• Spot opportunities others may be ignoring by reviewing the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.